a Record control number 000290726700015

a ISSN 1569-9056

a Original cataloging agency NEU GrandLibrary

a Language code of text/sound track or separate title eng

a Classification number WJ 300

b Item number .R48 2011

a Personal name Gunay, Mert.

h Medium Electronic Document

a Title Retroperitoneal Lymph Node Dissection for the Primary Treatment Recommendation in Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Contrary to European Guidelines.

c Statement of responsibility, etc Mert Gunay, Bulent Akdogan, Cemil Uygur, Haluk Ozen.

c Date of publication, distribution, etc 2011.

b Name of publisher, distributor, etc Elsevier,

a Place of publication, distribution, etc Amsterdam :

a Summary, etc Context: The optimal management strategy for clinical stage I (CS1) non-seminomatous germ cell tumors (NSGCTs) of the testis is controversial. Objective: Evidence is presented to suggest that retroperitoneal lymph node dissection (RPLND) is among the primary treatment options in the management of CS1 NSGCTs. Evidence acquisition: A nonsystematic search performed in January 2011 was used to identify relevant literature regarding advantages of RPLND as the primary adjuvant therapy for CS1 NSGCT after orchiectomy. Evidence synthesis: European guidelines follow a risk-adapted strategy for the primary management of CS1 NSGCTs based on the presence of vascular invasion. Surveillance is recommended as the primary treatment option for the low-risk group, whereas two cycles of platin-based chemotherapy is suggested for high-risk patients. Aside from the benefits of this strategy, there are some drawbacks that surgery may ameliorate. The absence of accurate prognostic markers compels risk adaptation. The difficulties in radiologic staging of retroperitoneum, the high relapse rates in surveillance, the long-term toxicity of chemotherapy, and a teratoma component in retroperitoneal relapses are the main problems that nerve-sparing RPLND (ns-RPLND) can resolve with minimal morbidity. The ns-RPLND provides similar oncologic outcomes with better retroperitoneal staging and facilitation of follow-up for abdominal recurrences. Conclusions: Surveillance, adjuvant chemotherapy, and ns-RPLND are all accepted treatments for long-term survival. The ns-RPLND has similar merits to surveillance and adjuvant chemotherapy and should be presented to patients as an equal option. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

a Topical term or geographic name as entry element Urology.

a Topical term or geographic name as entry element Near East University Article

a Topical term or geographic name as entry element Yakın Doğu Üniversitesi Makale

a Topical term or geographic name as entry element Testicular cancer

a Topical term or geographic name as entry element Surveillance

a Topical term or geographic name as entry element Adjuvant chemotherapy

g Relationship information MAY 2011, Vol 10 Issue 3, pE75-E80

t Title European Urology Supplements

x International Standard Serial Number 15699056

u Uniform Resource Identifier http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.1016/j.eursup.2011.03.006